240 related articles for article (PubMed ID: 15311075)
1. Re: Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
Deger S
J Urol; 2004 Sep; 172(3):1198; author reply 1198. PubMed ID: 15311075
[No Abstract] [Full Text] [Related]
2. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer.
Pellizzon AC; Salvajoli JV; Maia MA; Ferrigno R; Novaes PE; Fogarolli RC; Pellizzon RJ
J Urol; 2004 Mar; 171(3):1105-8. PubMed ID: 14767280
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
5. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
[TBL] [Abstract][Full Text] [Related]
6. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
8. Urethral stricture following high dose rate brachytherapy for prostate cancer.
Sullivan L; Williams SG; Tai KH; Foroudi F; Cleeve L; Duchesne GM
Radiother Oncol; 2009 May; 91(2):232-6. PubMed ID: 19097660
[TBL] [Abstract][Full Text] [Related]
9. Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: a prospective assessment of acute and late treatment toxicity.
Wahlgren T; Nilsson S; Ryberg M; Lennernäs B; Brandberg Y
Acta Oncol; 2005; 44(6):633-43. PubMed ID: 16165923
[TBL] [Abstract][Full Text] [Related]
10. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
Kollmeier MA; Stock RG; Cesaretti J; Stone NN
J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
[TBL] [Abstract][Full Text] [Related]
11. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
Chrouser KL; Leibovich BC; Sweat SD; Larson DW; Davis BJ; Tran NV; Zincke H; Blute ML
J Urol; 2005 Jun; 173(6):1953-7. PubMed ID: 15879789
[TBL] [Abstract][Full Text] [Related]
12. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
13. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
14. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy.
Dörr W; Jaal J; Zips D
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999
[No Abstract] [Full Text] [Related]
16. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768
[TBL] [Abstract][Full Text] [Related]
17. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
18. High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women.
Fujikawa K; Miyamoto T; Ihara Y; Matsui Y; Takeuchi H
Gynecol Oncol; 2001 Jan; 80(1):21-3. PubMed ID: 11136564
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.
Morton GC; Loblaw DA; Chung H; Tsang G; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Batchelar D; Danjoux C; Szumacher E
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1299-305. PubMed ID: 20708853
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]